Cargando…
Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
BACKGROUND: The prognosis of patients with gastrointestinal stromal tumor (GIST) after the failure of standard therapies is poor with supportive care alone. Guidelines recommend clinical trials, and patients with good performance status following standard therapies are often eligible for phase I cli...
Autores principales: | Nagatani, Yoshiaki, Shitara, Kohei, Bando, Hideaki, Kuboki, Yasutoshi, Okamoto, Wataru, Kojima, Takashi, Yoshino, Takayuki, Nishida, Toshirou, Ohtsu, Atushi, Doi, Toshihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109764/ https://www.ncbi.nlm.nih.gov/pubmed/27842521 http://dx.doi.org/10.1186/s12885-016-2939-0 |
Ejemplares similares
-
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015) -
A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018) -
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019) -
Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors
por: Kawazoe, Akihito, et al.
Publicado: (2020) -
Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
por: Mishima, Saori, et al.
Publicado: (2018)